# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹691 Cr** Q1 FY'26 (+5%) · **₹657 Cr** prior year * **EBITDA:** **₹85 Cr** Q1 FY'26 · **₹72 Cr** prior year (+122 bps margin expansion) * **Gross Profit:** **₹202 Cr** Q1 FY'26 · **₹181 Cr** prior year * **EBITDA Margin:** **~12%** Q1 FY'26 (+100 bps) * **PAT Growth:** **+18%** YoY ## B. Revenue Growth * **Modest Top-Line Expansion:** Revenue growth at 5% reflects stable demand, with upside potential from recent product launches and portfolio repositioning. ## C. Profit Margins * **Sustained Margin Enhancement:** EBITDA margin expansion driven by disciplined **premiumization** and **exit from low-margin generics**, with further gains expected to be sustainable. * **Gross Margin Improvement:** Despite a prior period decline, gross profit grew significantly in absolute terms, indicating better cost control and favorable mix shift. * **Profitability Leverage:** Strong 18% PAT growth outpaces top-line, highlighting operating leverage and efficiency gains from strategic transformation. --- # 2. Product & Segment Mix ## A. Key Figures * **Sales Mix:** **75%** B2C · **23%** B2B · **2%** exports * **Product Mix:** **58%** premium products · **42%** other products ## B. Premium Product Sales * **Premiumization Accelerating:** Strong double-digit growth in Focused Maharatna and Maharatna lines, driven by successful repositioning from generic supplier to solution provider using new-generation molecules and advanced formulations. * **Brand & Market Acceptance:** At least **2 new products** launched in Focused Maharatna range with more entering Maharatna tier, reflecting robust pipeline uptake and farmer/distributor confidence. * **Strategic Cost Implication:** High selling expenses persist due to field-intensive B2C model requiring farmer training and retail collaboration, a structural feature of premium solution delivery. ## C. B2C vs B2B Split * **B2C Resilience, B2B Recovery Expected:** B2C growth offset B2B decline in Q1; management expects B2B rebound in Q2 and beyond, with no long-term shift in demand dynamics. * **Margin Sensitivity Ahead:** While B2C’s higher-margin profile boosted Q1 results, anticipated B2B recovery may temper margin expansion unless mix shifts toward **new-generation technology products** that preserve profitability. --- # 3. Capacity & Production ## A. Key Figures * **Plant Utilization:** **100%** across all factories * Dahej Capex: Part 1 complete with almost 100 reactors added; plant operational ## B. Plant Utilization * **Supply Constraints:** All factories running at full capacity amid strong agrochemical demand, indicating supply-side constraints despite robust market conditions. ## C. New Facility Timeline * **Sotanala Expansion:** Formulation unit slated for start in next kharif season; technical unit Phase 1 expected by end of next fiscal year. ## D. Capex Completion * **Dahej Operational Ramp:** Technical plant fully capitalized and in production, with full depreciation impact anticipated by year-end. --- # 4. Launches & Pipeline ## A. Key Figures * **Q1 Sales from New Launches:** **₹42 Cr** (vs. prior full-year: ₹34 Cr) ## B. New Product Rollout * **Accelerated Commercial Traction:** New product launches delivered stronger-than-expected Q1 sales, surpassing prior full-year levels, reflecting improved go-to-market timing and early adoption. * **Premium Portfolio Expansion:** Successful Q1 performers include Torry Super, Green Expert, Terrox, and Kunoichi, while SPARCLE—launched in Q2 in partnership with MNC Corteva—marks a strategic entry into high-value rice solutions. * **Next-Gen Innovation Gains Ground:** Altair, a patented herbicide for rice, has achieved **100% user satisfaction** across deployment geographies and is active in over 900 villages, with scale-up planned across kharif and rabi seasons. * **Digital Integration:** IIL’s digital strategy is now centered on innovation, farmer engagement, and tailored solutions, reinforcing its product rollout and market connectivity. ## C. JV Development Progress * **OAT Agrio JV on Track:** First product filing expected in 2025, launch in 2026; second product in cost-optimization phase with clear path to scalable production. Insecticide launch confirmed for 2026, dependent on Japan-sourced regulatory data. * **Global Rights Structured for Scale:** IIL holds exclusive rights in 12 key markets (including Indian subcontinent, Middle East, Africa) with first right of refusal to manufacture; OAT to commercialize rest of world—supporting global IP monetization. * **Kaeros Integration Underway:** Post-merger, initial third-party and IIL manufacturing completed in Q1; limited financial guidance available for FY26. * **Strategic Collaborations Active:** Beyond Corteva, multiple undisclosed partnerships are in the pipeline, with announcements reserved for product launch stages. ## D. Patent & Filing Status * **Robust IP Pipeline:** Joint venture has filed **a dozen patents**, with development visibility on third and fourth products; data generation is collaborative, enabling global regulatory submissions. * **Backward Integration Push:** Company is advancing local sourcing and indigenous production initiatives to reduce import reliance, though import levels remain above **₹500 Cr**. --- # 5. Demand & Crop Trends ## A. Key Figures * **Crop Advisors (CAs):** **1,300+** in Q1 (up from typical 900) * **Quarterly Sales Pattern:** **30%-30%-20%-20%** (Q1-Q4) ## B. Herbicide Performance * **Divergent Demand:** Herbicide performance split on regional weather, with weak demand in dry crops (cotton, soybean) but **exceptional strength in paddy, rice, and maize**, where sales near all-time highs. * **Product & Inventory Strategy:** Next-gen herbicide technologies gaining traction; selective Q2 clearance of two herbicide inventories under Insecticides (India) policy, but no broad channel buildup observed. ## C. Crop-Specific Demand * **Strategic Crop Focus:** Company positioning as a solution provider in **rice, corn, soybean, wheat, sugarcane, horticulture, and pulses**, backed by a robust product pipeline. * **High-Value Crop Leverage:** South India remains a key market, with **chili driving outsized sales** due to high spray frequency despite limited acreage. ## D. Seasonal Sales Pattern * **Peak Season Pressure:** **July and August seeing immense demand**, creating supply chain challenges; strong nationwide pull expected to drive down company and trade inventories month-on-month. * **Rabi Momentum Building:** Altair’s field-intensive model with expanded on-ground team and **thousands of farmer engagements in Q1** supports strong sentiment ahead of rabi season. --- # 6. Risks & Weather Exposure ## A. Key Figures * **Raw Material Imports:** **₹500–600 Cr** annually (stable 3–4 years) · dipped to **₹450 Cr** in some years * **Sales Returns Provision:** **₹60–70 Cr** expected in Q2, primarily related to Q1 products * Normal Sales Returns: 3% of revenue (normal routine) ## B. Monsoon Variability * **Favorable Overall Conditions:** Southwest monsoon delivered normal rainfall with strong start and healthy reservoirs, though **uneven regional distribution** caused localized dry and wet spells affecting crop health. * **Herbicide Demand Hit in June:** Muted demand in dry crops like cotton and soybean due to low rainfall early in the season. ## C. Input Price Uncertainty * **Stable Cost Environment:** Raw material prices remain near post-COVID lows with minimal fluctuations, resulting in no significant cost pressures. * **Procurement Ahead of Curve:** Company has secured key inputs through October for kharif and already procured for rabi, mitigating near-term supply and pricing risks. ## D. Sales Return Volatility * **Elevated Returns Expected:** Q2 to see higher-than-normal sales returns due to adverse conditions in soybean, where company has strong exposure and recent product launch. * **Impact Contained and Managed:** Returns from Q1 will reverse in August; company is actively offsetting impact by pushing rice herbicides, insecticides, and fungicides with strong demand. --- # 7. Guidance & Outlook ## A. Key Figures * **FY '27 Revenue (Kaeros):** **₹150–200 Cr** (target: ~₹100 Cr this year) * **Maturity Revenue (05 Lakh Acres):** **₹70 Cr** expected * **EBITDA Margin Target:** Maintain current levels · **>100 bps improvement** targeted forward ## B. Revenue Projections * **Kaeros Growth Trajectory:** Revenue set for meaningful scale-up into FY '27, with current-year target nearing **₹100 Cr**, reflecting strong commercialization momentum. * **Seasonal Trend Normalization:** Q2 expected to rebound to **broadly in-line** with Q1 performance after two subdued years, indicating return to historical seasonality. * **Milestone Monetization:** Revenue from mature operations tied to **05 lakh acres** nearing **₹70 Cr**, validating scalability of core platform. ## C. Margin Targets * **Margin Resilience:** EBITDA margins held firm despite scaling investments, with **>120 bps YoY improvement** achieved and further expansion of **over 100 bps** targeted. ## D. Growth Initiatives * **Premium & B2C Expansion:** **Double-digit growth** expected in B2C segment, with **premium products** targeted at **20% growth**, driving profitability uplift. * **Strategic Scaling:** Long-term **Altair** goal set at **5 lakh acres in 2–3 years**, backed by capex execution and expanded product pipeline. * **Growth Enablers:** **Farmer engagement** and new product launches identified as key catalysts for sustained market penetration.